-

AGTI Investor Notice: Robbins LLP Reminds Shareholders it is Investigating the Acquisition of Agiliti Inc. by THL Partners

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Agiliti, Inc. (NYSE: AGTI) by private equity firm Thomas H. Lee Partners, L.P. ("THL"). Under the terms of the agreement, Agiliti stockholders will receive $10.00 in cash for each share of Agiliti common stock owned.

If you own shares of Agiliti, Inc. click here.

Is the Proposed Acquisition Best for Agiliti, Inc. (AGTI) and its Shareholders?

On February 26, 2024, Agiliti announced a deal to be acquired by THL. According to the Proxy Statement, Agiliti's board of directors approved the merger agreement for $10.00 per share in cash. The deal is valued at approximately $2.5 billion and is expected to close in the first half of 2024. Robbins LLP is concerned that Agiliti's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of Agiliti, Inc. (AGTI) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion in value for shareholders. To be notified if a class action against Agiliti, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AGTI

Release Summary
Robbins LLP is investigating the acquisition of Agiliti Inc. (AGTI) by THL Partners
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Graphic Packaging Holding Company Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Graphic Packaging Holding Company (NYSE: GPK) common stock between February 4, 2025 and February 2, 2026. Graphic Packaging, together with its subsidiaries, designs, produces, and sells consumer packaging products. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbin...

Babcock & Wilcox Enterprises, Inc. Class Action Reminder - Robbins LLP Encourages BW Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Babcock & Wilcox Enterprises, Inc. (NYSE: BW) securities between November 5, 2025 and March 11, 2026. Babcock & Wilcox provides energy and emissions control solutions to industrial, electrical utility, municipal, and other customers in the U.S., Canada, the U.K., Indonesia, and the Philippines.For more information, submit a form, email...

Investor Notice: Robbins LLP Informs Investors of the Immutep Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company’s product pipeline includes TACTI-004, which is in phase II...
Back to Newsroom